StreetInsider.com News Articles

Fate Therapeutics names Jamie Harrell SVP of commercial operations

Mon, 12 Oct 2026 07:00:28 -0400

Fate Therapeutics, Inc. (NASDAQ: FATE) appointed Jamie Harrell as Senior Vice President of Market Development and Commercial Operations, effective Oct. 12, 2026, according to a press release from the San Diego-based company.

Harrell will lead commercial and market development strategy across Fate's autoimmunity and oncology programs. His responsibilities include overseeing commercialization efforts tied to FT819, which is being evaluated in RECLAIM-LN, a Phase 2 trial in refractory lupus nephritis, and FT839, which is in a Phase 1/2 trial across multiple autoimmune indications including rheumatoid arthritis.

Harrell brings more than 25 years of commercial experience. He most recently served as Vice President of

Fate Therapeutics names Jamie Harrell as commercial operations chief

Mon, 12 Oct 2026 07:00:15 -0400

Fate Therapeutics, Inc. (NASDAQ: FATE) has appointed Jamie Harrell as Senior Vice President of Market Development and Commercial Operations, effective October 12, 2026, according to a company statement.

Harrell, who brings more than 25 years of commercial leadership experience, will oversee commercial and market development strategy across the San Diego-based company's autoimmunity and oncology programs. His responsibilities include developing physician engagement strategy and expanding access to the company's off-the-shelf CAR T-cell therapies in outpatient and community settings.

The role was newly created to support Fate Therapeutics as it advances its pipeline toward commercialization, including FT819, which is being evaluated in RECLAIM-LN, a

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Mon, 12 Oct 2026 07:00:00 -0400

Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial

Proven record in advancing breakthrough autoimmune therapies and establishing novel lupus treatments in community settings

SAN DIEGO, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative and broadly accessible pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced the appointment of Jamie Harrell to its executive leadership team, effective October 12, 2026.

Mr.

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Mon, 12 Oct 2026 07:00:00 -0400

Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial

Proven record in advancing breakthrough autoimmune therapies and establishing novel lupus treatments in community settings

Mr.

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Mon, 12 Oct 2026 07:00:00 -0400

Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial

Proven record in advancing breakthrough autoimmune therapies and establishing novel lupus treatments in community settings

Mr.

Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies

Mon, 12 Oct 2026 07:00:00 -0400

Commercial leader brings lupus nephritis and first-in-class launch experience as FT819 advances in the RECLAIM-LN Phase 2 trial

Proven record in advancing breakthrough autoimmune therapies and establishing novel lupus treatments in community settings

Mr.

Entera Bio adds former Gilead executive Laura Hamill to its board

Tue, 06 Oct 2026 08:00:50 -0400

Entera Bio Ltd. (NASDAQ: ENTX) announced the appointment of Laura Hamill to its Board of Directors, effective December 1, 2026. Hamill succeeds Yonatan Malca, who is stepping down after 16 years of service.

Hamill brings more than 35 years of biopharmaceutical commercial leadership experience. Most recently, she served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences, where she led an organization of approximately 2,500 employees responsible for $22 billion in annual revenue.

Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw

Entera Bio adds former Gilead executive Laura Hamill to its board

Tue, 06 Oct 2026 08:00:50 -0400

Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw

Entera Bio adds former Gilead executive Laura Hamill to its board

Tue, 06 Oct 2026 08:00:50 -0400

Prior to Gilead, Hamill spent nearly two decades at Amgen in roles of increasing scope, including Senior Vice President of U.S. Commercial Business Operations, where she oversaw

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

Tue, 06 Oct 2026 08:00:00 -0400